Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
10.40
-0.26 (-2.44%)
Nov 21, 2024, 10:59 AM EST - Market open
Benitec Biopharma Employees
Benitec Biopharma had 16 employees as of June 30, 2024. The number of employees decreased by 2 or -11.11% compared to the previous year.
Employees
16
Change (1Y)
-2
Growth (1Y)
-11.11%
Revenue / Employee
n/a
Profits / Employee
-$1,303,500
Market Cap
241.45M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Aurora Cannabis | 1,073 |
Inogen | 834 |
TScan Therapeutics | 154 |
Biomea Fusion | 103 |
aTyr Pharma | 59 |
Cybin | 50 |
Trevi Therapeutics | 25 |
Eledon Pharmaceuticals | 20 |
BNTC News
- 6 days ago - Benitec Biopharma Releases First Quarter 2025 Financial Results and Provides Operational Update - GlobeNewsWire
- 17 days ago - Benitec Biopharma CEO to Participate in the Guggenheim Securities Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Benitec Biopharma: OPMD Program Continues To Advance With Catalysts - Seeking Alpha
- 5 weeks ago - Benitec Biopharma Announces Updated Investor Webcast Information - GlobeNewsWire
- 5 weeks ago - Benitec Biopharma Reports Positive Data from Two Subjects Treated with Low-Dose BB-301 in Phase 1b/2a Study Presented at 29th Annual Congress of the World Muscle Society - GlobeNewsWire
- 7 weeks ago - Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update - GlobeNewsWire
- 2 months ago - Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society - GlobeNewsWire
- 4 months ago - Benitec Biopharma Reports Continued Durable Improvements in the Radiographic Assessments of Swallowing Efficiency and the Subject-Reported Outcome Instrument at the 180-Day Timepoint for First OPMD Subject Treated with Low-Dose BB-301 in Phase 1b/2a Study - GlobeNewsWire